Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-2990 in endometriosis-related pain
NCT03840993Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jan 2019
- Primary completion
- May 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in endometriosis comparing MT-2990 with Placebo (2 arms). Primary endpoint: Nonmenstrual Pelvic Pain (0-3 scale) at 16 weeks. Started Jan 2019; status: completed.
02
Drugs
MT-2990
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT03840993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03840993.